R-HDAC

R-HDAC, or R-HD-AraC ((R)ituximab plus (H)igh (D)ose (A)ra-(C)) is a chemotherapy regimen that is used, alternating with R-Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma. It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine.[1]

High-dose Ara-C (HDAC) without rituximab also has several other uses in oncohematology. For example, HDAC, alone or alternating with HD-MTX, is often used for primary CNS lymphoma and for treating CNS involvement in any lymphomas, and also for so-called "CNS prophylaxis" (prophylactic use in those forms of lymphoma which show no signs of CNS involvement at diagnosis but have high chance of CNS relapse or recurrence). HDAC is also used as a consolidation regimen in acute myeloid leukemia after initial 7+3 induction. HDAC also can be used as the primary induction therapy in AML, with higher than in 7+3 success (remission) rate, but it is more toxic and causes more treatment-related complications and treatment-related mortality than 7+3 when used as primary induction therapy.

Dosing regimen

Drug Dose Mode Days
(R)ituximab 375 mg/m² IV infusion Day 1
(H)igh (D)ose (A)ra-(C)ytarabine 3000 mg/m² IV infusion Days 1 and 2

References

  1. ↑ Nordic Protocol (Maxi-CHOP and High Dose Cytarabine) for Mantle Cell Lymphoma (MCL)
This article is issued from Wikipedia - version of the 3/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.